761 logo

Pharmanutra S.p.A.DB:761 Stock Report

Market Cap €854.1m
Share Price
n/a
1Y85.8%
7D0.7%
1D0.6%
Portfolio Value
​
View

Pharmanutra S.p.A.

DB:761 Stock Report

Market Cap: €854.1m

Pharmanutra (761) Stock Overview

A nutraceutical company, engages in the research and development and marketing of food supplements and medical devices in Europe, the Middle East, Far East, North America, South America, and internationally. More details

761 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth4/6
Past Performance6/6
Financial Health5/6
Dividends2/6

Rewards

Earnings are forecast to grow 19.78% per year

Earnings grew by 28.1% over the past year

Risk Analysis

No risks detected for 761 from our risk checks.

761 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW494,830 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
BL
BlackGoat
IN
Investingwilly
RO
RockeTeller
AG
Agricola
494,830 investors already sharing narratives
View all narratives

Pharmanutra S.p.A. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Pharmanutra
Historical stock prices
Current Share Price€86.50
52 Week High€94.00
52 Week Low€38.55
Beta0.19
1 Month Change-5.88%
3 Month Change11.76%
1 Year Change85.82%
3 Year Change45.38%
5 Year Change70.95%
Change since IPO133.78%

Recent News & Updates

Recent updates

Shareholder Returns

761DE Personal ProductsDE Market
7D0.7%-0.4%3.8%
1Y85.8%-3.2%3.9%

Return vs Industry: 761 exceeded the German Personal Products industry which returned -3.2% over the past year.

Return vs Market: 761 exceeded the German Market which returned 3.9% over the past year.

Price Volatility

Is 761's price volatile compared to industry and market?
761 volatility
761 Average Weekly Movement5.8%
Personal Products Industry Average Movement5.0%
Market Average Movement5.6%
10% most volatile stocks in DE Market12.5%
10% least volatile stocks in DE Market2.7%

Stable Share Price: 761 has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: 761's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2000140n/awww.pharmanutra.it

Pharmanutra S.p.A., a nutraceutical company, engages in the research and development and marketing of food supplements and medical devices in Europe, the Middle East, Far East, North America, South America, and internationally. The company produces and distributes raw materials and active ingredients for the food, pharmaceutical, and dietary supplement industries. It offers Sucrosomial, a delivery system that optimises nutrient transport and absorption for minimising gastrointestinal side effects; and Cetylated Fatty Acids, a formulation for muscle and joint recovery in physiotherapy and sports.

Pharmanutra S.p.A. Fundamentals Summary

How do Pharmanutra's earnings and revenue compare to its market cap?
761 fundamental statistics
Market cap€854.11m
Earnings (TTM)€21.02m
Revenue (TTM)€138.94m
40.6x
P/E Ratio
6.1x
P/S Ratio

Is 761 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
761 income statement (TTM)
Revenue€138.94m
Cost of Revenue€68.31m
Gross Profit€70.63m
Other Expenses€49.61m
Earnings€21.02m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)2.20
Gross Margin50.83%
Net Profit Margin15.13%
Debt/Equity Ratio23.5%

How did 761 perform over the long term?

See historical performance and comparison

Dividends

1.3%
Current Dividend Yield
55%
Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/05 08:07
End of Day Share Price 2026/07/03 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Pharmanutra S.p.A. is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Anna FrontaniBerenberg
Andrea RandoneIntermonte SIM S.p.A.
Giorgio TavoliniIntermonte SIM S.p.A.